Schrodinger, Inc.
SDGR Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$24.50
KIRA · Stoqly’s AI analyst, in plain words
- Schrodinger, Inc. had $256M of revenue in fiscal 2025, up 23.3% on the year before. Over five years, revenue changed +18.8% a year on average.
- Its operating margin was −65.2%, up 35.6 pts: of every 100 in sales, about −65 is left after running the business.
- Schrodinger, Inc. lost $103M in fiscal 2025.
- Free cash flow was $12.5M in fiscal 2025, 4.9% of revenue.
Market cap
$1.9B
P/E
—
Revenue
$256M
Net income
−$103M
Free cash flow
$12.5M
Operating margin
−65.2%
Schrodinger, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+23.3%
Yes. Sales grew 23.3% last year.
Does it make a profit?
−40.4%
No. It lost money last year.
Does profit turn into cash?
4.9%
Partly. 4.9% of sales ends up as free cash.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Schrodinger, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Schrodinger, Inc.
- CIK
- 0001490978
Schrodinger, Inc. · SDGR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $138M | $181M | $217M | $208M | $256M |
| Revenue growth | 27.6% | 31.2% | 19.7% | −4.2% | 23.3% |
| Gross margin | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% |
| Operating margin | −80.8% | −81.1% | −81.9% | −100.8% | −65.2% |
| Net income | −$100M | −$149M | $40.7M | −$187M | −$103M |
| Net margin | −72.8% | −82.4% | 18.8% | −90.2% | −40.4% |
| Diluted EPS | −$1.42 | −$2.10 | $0.54 | −$2.57 | −$1.41 |
| Cash | |||||
| Cash from operations | −$70.7M | −$120M | −$137M | −$157M | $13.9M |
| Capital expenditure | $7.2M | $8.0M | $13.4M | $7.3M | $1.4M |
| Free cash flow | −$77.8M | −$128M | −$150M | −$165M | $12.5M |
| FCF margin | −56.4% | −70.6% | −69.3% | −79.3% | 4.9% |
| Share count change | 17.6% | 0.8% | 5.4% | −3.1% | 1.1% |
| Debt and strength | |||||
| Cash and short-term investments | $576M | $451M | $463M | $352M | $395M |
| Shareholders' equity | $557M | $448M | $549M | $421M | $364M |
| Current ratio | 6.9x | 4.9x | 4.2x | 3.3x | 2.7x |
| Returns and quality | |||||
| Return on equity | −17.0% | −29.7% | 8.2% | −38.6% | −26.3% |
| Return on tangible equity | −18.0% | −33.7% | 7.5% | −44.9% | −28.7% |
| Piotroski F-score | 2 | 3 | 4 | 2 | 4 |
| Altman Z'' | 5.6 | 2.8 | 3.0 | 0.8 | −0.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.3M
7 insiders
Of sales under plans
100%
$2.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Schrodinger, Inc. · SDGR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $24.50 a share, the company is worth $1.9B.
Source: SEC EDGAR XBRL filings (CIK 0001490978). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.